Leading the CeNeRx portfolio is a phase I antidepressant, Tyrima™ (CX157) supported
by two backup candidates (CX2614 & CX009) known as reversible inhibitors of
monoamine oxidase- A (RIMA). This antidepressant series works by increasing levels
of the three key neurotransmitters associated with mood, anxiety and somatic
disorders.
by two backup candidates (CX2614 & CX009) known as reversible inhibitors of
monoamine oxidase- A (RIMA). This antidepressant series works by increasing levels
of the three key neurotransmitters associated with mood, anxiety and somatic
disorders.
• Well-Precedented Mechanism
- Triple-action Mechanism (Serotonin, Norepinephrine, Dopamine)
• Wide Therapeutic Window
• Highly Selective & Reversible
- Significantly Reduces MAOI Risk of Tyramine “Cheese” Reaction
• Strong Intellectual Property with Market Exclusivity beyond 2026.
• Cost Effective, Simple Synthesis (Low COGS)
• Favorable Pharmacokinetics – Once Daily Dosing
• Multiple Compounds / Back Ups = Multiple Shots on Goal
- Triple-action Mechanism (Serotonin, Norepinephrine, Dopamine)
• Wide Therapeutic Window
• Highly Selective & Reversible
- Significantly Reduces MAOI Risk of Tyramine “Cheese” Reaction
• Strong Intellectual Property with Market Exclusivity beyond 2026.
• Cost Effective, Simple Synthesis (Low COGS)
• Favorable Pharmacokinetics – Once Daily Dosing
• Multiple Compounds / Back Ups = Multiple Shots on Goal
• Broad Portfolio of Cannabinoids
- CB1 / CB2
- Agonists / Antagonists
- CNS / Non-CNS Penetrant
• Proof of Concept in Pain (Tail Flick, Hot Plate)
• Proof of Concept in Obesity
• Market Exclusivity Beyond 2025
- CB1 / CB2
- Agonists / Antagonists
- CNS / Non-CNS Penetrant
• Proof of Concept in Pain (Tail Flick, Hot Plate)
• Proof of Concept in Obesity
• Market Exclusivity Beyond 2025
Tyrima™ *